The multiple ascending dose trial in healthy volunteers confirmed that BBT002 effectively targets IL-4Rα and IL-5, two critical drivers of respiratory inflammation. Clinical findings showed rapid and sustained depletion of eosinophils, alongside the inhibition of pSTAT6 and TARC levels for over eight weeks. Researchers noted that the drug maintained a half-life of approximately 29.4 days, a profile that could improve convenience for those managing chronic conditions.

Thang Ho, Chief Development Officer at Bambusa, stated that the data reinforces the antibody's potential to provide comprehensive disease control. Safety profiles remained consistent across all cohorts, with low incidence of anti-drug antibodies reported. As the company moves forward, it is currently evaluating BBT002 in proof-of-concept studies for chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps, with primary data expected to arrive by the end of 2026 and early 2027.